You've been managing your cholesterol the best you can, but during your last check-up, you received the same message: Your ...

A single infusion of an experimental gene-editing therapy called VERVE-102 lowered LDL cholesterol in people with dangerously high lipid levels, marking the first time in vivo base editing of the ...

In 2015, when the first cholesterol-lowering drugs targeting a protein called PCSK9 were about to hit the market, anticipation in the cardiovascular community ran high. Elevated levels of low-density ...

PCSK9 antibodies effectively lower the LDL-cholesterol level and, therefore, address an unmet clinical need in patients with either refractory hypercholesterolaemia, statin intolerance, or an elevated ...

DelveInsight's PCSK9 Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, emerging PCSK9 ...

Globally, atherosclerotic cardiovascular disease (ASCVD) is the primary cause of illness and death and is much more common in with type 2 diabetes mellitus (T2DM) patients than non-diabetic ...

Richa Munjal considers the current landscape for PCSK9 inhibitors and whether there is a brighter future on the horizon for this class of drugs. The promise of a new era of cholesterol management, ...

On Friday, for the first time, we saw the full data from the FOURIER clinical trial of Amgen’s cholesterol-lowering antibody, evolocumab (Repatha). Depending on who you listen to, it was either “the ...

A peptide vaccine targeting PCSK9 has demonstrated sustained antibody responses and reductions in LDL cholesterol and atherosclerotic plaque formation in animal models, offering a potential long-term ...

Wilmington, Delaware, United States, Transparency Market Research Inc.-, Feb. 10, 2025 (GLOBE NEWSWIRE) -- The PCSK9 Inhibitor Market (Markt für PCSK9-Inhibitoren) is poised for significant growth, ...

A draft report on the value-based price benchmark for the newly approved PCSK9 inhibitors for lowering bad cholesterol found that Repatha and Praluent should cost approximately 85% less than their ...